Filing Flows › Krystal Biotech (KRYS) › R&D spending
Krystal Biotech (KRYS) R&D spending by quarter
Krystal Biotech's R&D spending was $14.9M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 7 quarters it ranged from $14.3M (Q1 2025) to $15.3M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.9M | +3% | +2% |
| Q2 2026 | $14.5M | -5% | +0.7% |
| Q1 2026 | $15.3M | +4% | +8% |
| Q4 2025 | $14.8M | +1% | — |
| Q3 2025 | $14.6M | +1% | — |
| Q2 2025 | $14.4M | +1% | — |
| Q1 2025 | $14.3M | — | — |
Q3 2026 at a glance
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Krystal Biotech's R&D spending?
Krystal Biotech's R&D spending was $14.9M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has Krystal Biotech's R&D spending changed?
Over the last 7 quarters it ranged from $14.3M (Q1 2025) to $15.3M (Q1 2026).